Clinical Trial Update: Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating dupilumab to improve circadian function, sleep, and pruritus in children with moderate-to-severe atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Northwestern University | Conditions: Atopic Dermatitis, Sleep Disturbance | Phase 4 | Status: RECRUITING